Purpose. Comparative analysis of the quality of life profiles in patients with various vitreoretinal diseases. Material and methods. The study included 76 patients with established diseases of the retina and vitreous body aged 17 to 82 years, of which 25 were men and 51 were women. All participants were interviewed using a special questionnaire assessment of vision Visual Functioning Questionnaire 25 (VFQ-25). Quantitative data are processed using descriptive statistics and presented as medians and quartiles. The reliability of differences between patients from different observation groups was confirmed by nonparametric statistics (the Mann–Whitney test). The reliability of the differences was considered established at p<0.05. Results. The results of patients' subjective assessment of various social aspects of their life activity are shown. The results of a comparative assessment of quality of life indicators depending on the diagnosis are given. Conclusion. The quality of life profile of patients with vitreoretinal pathology is characterized by a low assessment of patients ‘General health status and a high level of dependence on external assistance. Patients experience significant difficulties when driving a car. There is also a low level of role difficulties reflecting the individual's adaptive reserves in society. There were significant differences in the levels of assessment of quality of life indicators by respondents with various vitreoretinal diseases on the scales: «General health», «near visual function». Key words: quality of life, diseases of the posterior segment of the eye, VFQ-25 questionnaire, ophthalmological patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.